{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T06:51:29Z","timestamp":1769842289610,"version":"3.49.0"},"reference-count":44,"publisher":"Becaris Publishing Limited","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            There is growing interest in novel insulin management systems that improve glycemic control. This study aimed to evaluate the cost\u2013effectiveness of smart connected insulin re-usable pens or caps for disposable insulin pens versus pens without connected capabilities in the management of adult patients with Type 1 diabetes (T1DM) from a Canadian societal perspective.\n            <jats:bold>Materials &amp; methods:<\/jats:bold>\n            The IQVIA Core Diabetes Model was utilized to conduct the analyses. Applying data from a non-interventional study, the connected insulin device arm was assumed to result in greater reductions (-0.67%) in glycated hemoglobin from baseline and fewer non-severe hypoglycemic events (-32.87 events\/patient annually). Macro- and micro-vascular risks were predicted using the Epidemiology of Diabetes Interventions and Complications study data. Direct and indirect costs and utilities were sourced from literature. Key model outcomes included life years and quality-adjusted life-years (QALYs). Both costs and effects were annually discounted at 1.5% over a 60-year time horizon. Uncertainty was explored in scenario and probabilistic sensitivity analyses (PSA).\n            <jats:bold>Results:<\/jats:bold>\n            The connected insulin pen device was associated with lower mean discounted total costs (CAD221,943 vs 266,199; -CAD44,256), improvement in mean life expectancy (25.78 vs 24.29; +1.49\u00a0years) and gains in QALYs (18.48 vs 16.74; +1.75 QALYs) over the patient's lifetime. Most scenario analyses confirmed the base case results. The PSA showed dominance in 99.5% of cases.\n            <jats:bold>Conclusion:<\/jats:bold>\n            For adults with T1DM in Canada, a connected insulin pen device is likely to be a cost-effective treatment option associated with greater clinical benefits and lower costs relative to a standard re-usable or disposable pen.\n          <\/jats:p>","DOI":"10.57264\/cer-2023-0124","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T10:43:08Z","timestamp":1704969788000},"source":"Crossref","is-referenced-by-count":5,"title":["Smart connected insulin dose monitoring technologies versus standard of care: a Canadian cost\u2013effectiveness analysis"],"prefix":"10.57264","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0638-8352","authenticated-orcid":false,"given":"Katalina","family":"Chan","sequence":"first","affiliation":[{"name":"Novo Nordisk Canada, Inc., Patient Access, Mississauga, Ontario, L5N 6M1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K\u00e5re","family":"Hansen","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, Global Market Access, Novo All\u00e9 1, 2880, Bagsv\u00e6rd, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4105-4609","authenticated-orcid":false,"given":"Sergey","family":"Muratov","sequence":"additional","affiliation":[{"name":"IQVIA, Real World Solutions (RWS), Mississauga, Ontario, L4W 5N9, Canada"},{"name":"Department of Health Research Methods, McMaster University, Evidence, and Impact (HEI), Hamilton, Ontario, L8S 4L8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoghag","family":"Khoudigian","sequence":"additional","affiliation":[{"name":"IQVIA, Real World Solutions (RWS), Mississauga, Ontario, L4W 5N9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Lamotte","sequence":"additional","affiliation":[{"name":"Th(is)2Modeling bv, Hogeweg, 91730, Asse, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"key":"e_1_3_7_2_2","unstructured":"Public Health Agency of Canada. Diabetes In Canada: Highlights From The Canadian Chronic Disease Surveillance System (2017). https:\/\/www.canada.ca\/content\/dam\/phac-aspc\/documents\/services\/publications\/diseases-conditions\/diabetes-canada-highlights-chronic-disease-surveillance-system\/diabetes-in-canada-eng.pdf"},{"key":"e_1_3_7_3_2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jcjd.2017.10.001","article-title":"Clinical practice guidelines for the prevention and management of diabetes in Canada: introduction","volume":"42","author":"Houlden RL","year":"2018","unstructured":"Houlden RL. Clinical practice guidelines for the prevention and management of diabetes in Canada: introduction. Can. J. Diabetes 42, S1\u2013S5 (2018).","journal-title":"Can. J. Diabetes"},{"key":"e_1_3_7_4_2","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1007\/s00125-003-1116-6","article-title":"Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes","volume":"46","author":"Laing SP","year":"2003","unstructured":"Laing SP, Swerdlow AJ, Slater SD Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia 46, 760\u2013765 (2003).","journal-title":"Diabetologia"},{"key":"e_1_3_7_5_2","doi-asserted-by":"crossref","first-page":"e1001321","DOI":"10.1371\/journal.pmed.1001321","article-title":"Risk of cardiovascular disease and total mortality in adults with Type 1 diabetes: Scottish Registry Linkage Study","volume":"9","author":"Livingstone SJ","year":"2012","unstructured":"Livingstone SJ, Looker HC, Hothersall EJ Risk of cardiovascular disease and total mortality in adults with Type 1 diabetes: Scottish Registry Linkage Study. PLoS Med. 9, e1001321 (2012).","journal-title":"PLoS Med."},{"key":"e_1_3_7_6_2","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/dme.12858","article-title":"Impact of diabetes on healthcare costs in a population-based cohort: a cost analysis","volume":"33","author":"Rosella LC","year":"2016","unstructured":"Rosella LC, Lebenbaum M, Fitzpatrick T Impact of diabetes on healthcare costs in a population-based cohort: a cost analysis. Diabet. Med. 33, 395\u2013403 (2016).","journal-title":"Diabet. Med."},{"key":"e_1_3_7_7_2","unstructured":"Diabetes Canada. New Data Shows Diabetes Rates And Economic Burden On Families Continue To Rise In Ontario (2019). https:\/\/www.diabetes.ca\/media-room\/press-releases\/new-data-shows-diabetes-rates-and-economic-burden-on-families-continue-to-rise-in-ontario--"},{"issue":"1","key":"e_1_3_7_8_2","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/j.jcjd.2017.10.012","article-title":"Glycemic management in adults with Type 1 diabetes","volume":"42","author":"McGibbon A","year":"2018","unstructured":"McGibbon A, Adams L, Ingersoll K, Kader T, Tugwell B. Glycemic management in adults with Type 1 diabetes. Can. J. Diabetes 42(Suppl. 1), S80\u2013S87 (2018).","journal-title":"Can. J. Diabetes"},{"key":"e_1_3_7_9_2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1089\/dia.2020.0204","article-title":"The Canadian LMC Diabetes Registry: a profile of the demographics, management, and outcomes of individuals with Type 1 diabetes","volume":"23","author":"Aronson R","year":"2021","unstructured":"Aronson R, Brown RE, Abitbol A The Canadian LMC Diabetes Registry: a profile of the demographics, management, and outcomes of individuals with Type 1 diabetes. Diabetes Technol. Ther. 23, 31\u201340 (2021).","journal-title":"Diabetes Technol. Ther."},{"key":"e_1_3_7_10_2","doi-asserted-by":"crossref","unstructured":"CADTH. Hybrid Closed-Loop Insulin Delivery Systems for People with Type 1 Diabetes (2020). https:\/\/www.cadth.ca\/sites\/default\/files\/ou-tr\/de0104-hcl-insulin-scoping-brief-final.pdf","DOI":"10.51731\/cjht.2021.89"},{"key":"e_1_3_7_11_2","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1089\/dia.2018.0384","article-title":"State of Type 1 diabetes management and outcomes from the T1D Exchange in 2016\u20132018","volume":"21","author":"Foster NC","year":"2019","unstructured":"Foster NC, Beck RW, Miller KM State of Type 1 diabetes management and outcomes from the T1D Exchange in 2016\u20132018. Diabetes Technol. Ther. 21, 66\u201372 (2019).","journal-title":"Diabetes Technol. Ther."},{"key":"e_1_3_7_12_2","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.diabet.2018.08.012","article-title":"Digital diabetes: perspectives for diabetes prevention, management and research","volume":"45","author":"Fagherazzi G","year":"2019","unstructured":"Fagherazzi G, Ravaud P. Digital diabetes: perspectives for diabetes prevention, management and research. Diabetes Metab. 45, 322\u2013329 (2019).","journal-title":"Diabetes Metab."},{"key":"e_1_3_7_13_2","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.2337\/dc16-0346","article-title":"Do mobile phone applications improve glycemic control (HbA1c) in the self-management of diabetes? A systematic review, meta-analysis, and GRADE of 14 randomized trials","volume":"39","author":"Hou C","year":"2016","unstructured":"Hou C, Carter B, Hewitt J, Francisa T, Mayor S. Do mobile phone applications improve glycemic control (HbA1c) in the self-management of diabetes? A systematic review, meta-analysis, and GRADE of 14 randomized trials. Diabetes Care 39, 2089\u20132095 (2016).","journal-title":"Diabetes Care"},{"issue":"10","key":"e_1_3_7_14_2","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1089\/dia.2022.0134","article-title":"Real-world evidence of improved glycemic control in people with diabetes using a bluetooth-connected blood glucose meter with a mobile diabetes management app","volume":"24","author":"Grady M","year":"2022","unstructured":"Grady M, Cameron H, Bhatiker A, Holt E, Schnell O. Real-world evidence of improved glycemic control in people with diabetes using a bluetooth-connected blood glucose meter with a mobile diabetes management app. Diabetes Technol. Ther. 24(10), 770\u2013778 (2022).","journal-title":"Diabetes Technol. Ther."},{"key":"e_1_3_7_15_2","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.2337\/dc19-1459","article-title":"Effects of continuous glucose monitoring on metrics of glycemic control in diabetes: a systematic review with meta-analysis of randomized controlled trials","volume":"43","author":"Maiorino MI","year":"2020","unstructured":"Maiorino MI, Signoriello S, Maio A Effects of continuous glucose monitoring on metrics of glycemic control in diabetes: a systematic review with meta-analysis of randomized controlled trials. Diabetes Care 43, 1146\u20131156 (2020).","journal-title":"Diabetes Care"},{"key":"e_1_3_7_16_2","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1177\/1932296817713506","article-title":"A systematic review of reviews evaluating technology-enabled diabetes self-management education and support","volume":"11","author":"Greenwood DA","year":"2017","unstructured":"Greenwood DA, Gee PM, Fatkin KJ, Peeples M. A systematic review of reviews evaluating technology-enabled diabetes self-management education and support. J. Diabetes Sci. Technol. 11, 1015\u20131027 (2017).","journal-title":"J. Diabetes Sci. Technol."},{"key":"e_1_3_7_17_2","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1089\/dia.2019.0411","article-title":"Increased time in range and fewer missed bolus injections after introduction of a smart connected insulin pen","volume":"22","author":"Adolfsson P","year":"2020","unstructured":"Adolfsson P, Hartvig NV, Kaas A, M\u00f8ller JB, Hellman J. Increased time in range and fewer missed bolus injections after introduction of a smart connected insulin pen. Diabetes Technol. Ther. 22, 709\u2013718 (2020).","journal-title":"Diabetes Technol. Ther."},{"issue":"5","key":"e_1_3_7_18_2","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.3390\/s22051843","article-title":"Machine learning and smart devices for diabetes management: systematic review","volume":"22","author":"Makroum MA","year":"2022","unstructured":"Makroum MA, Adda M, Bouzouane A, Ibrahim H. Machine learning and smart devices for diabetes management: systematic review. Sensors (Basel) 22(5), 1843 (2022).","journal-title":"Sensors (Basel)"},{"key":"e_1_3_7_19_2","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.2337\/dc22-S007","article-title":"Diabetes Technology: Standards of Medical Care in Diabetes\u20142022","volume":"45","author":"American Diabetes Association Professional Practice Committee","year":"2021","unstructured":"American Diabetes Association Professional Practice Committee. Diabetes Technology: Standards of Medical Care in Diabetes\u20142022. Diabetes Care 45, S97\u2013S112 (2021).","journal-title":"Diabetes Care"},{"key":"e_1_3_7_20_2","unstructured":"Scottish Intercollegiate Guidelines Network. Management of diabetes: a national clinical guideline (2017). https:\/\/www.sign.ac.uk\/assets\/sign116.pdf"},{"key":"e_1_3_7_21_2","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1177\/19322968211058707","article-title":"Development of an insulin pen is a patient-centric multidisciplinary undertaking: a commentary","volume":"16","author":"Sparre T","year":"2021","unstructured":"Sparre T, Hansen N-AB, Wernersson AS, Guarraia M. Development of an insulin pen is a patient-centric multidisciplinary undertaking: a commentary. J. Diabetes Sci. Technol. 16, 617\u2013622 (2021).","journal-title":"J. Diabetes Sci. Technol."},{"key":"e_1_3_7_22_2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13643-020-01373-y","article-title":"cost\u2013effectiveness of health technologies in adults with Type 1 diabetes: a systematic review and narrative synthesis","volume":"9","author":"Pease A","year":"2020","unstructured":"Pease A, Zomer E, Liew D cost\u2013effectiveness of health technologies in adults with Type 1 diabetes: a systematic review and narrative synthesis. Syst. Rev. 9, 171 (2020).","journal-title":"Syst. Rev."},{"key":"e_1_3_7_23_2","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jval.2014.07.007","article-title":"Validation of the IMS CORE diabetes model","volume":"17","author":"McEwan P","year":"2014","unstructured":"McEwan P, Foos V, Palmer JL Validation of the IMS CORE diabetes model. Value Health 17, 714\u2013724 (2014).","journal-title":"Value Health"},{"issue":"1","key":"e_1_3_7_24_2","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1185\/030079904X1980","article-title":"The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost\u2013effectiveness of interventions in diabetes mellitus (Types 1 and 2) to support clinical and reimbursement decision-making","volume":"20","author":"Palmer AJ","year":"2004","unstructured":"Palmer AJ, Roze S, Valentine WJ The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost\u2013effectiveness of interventions in diabetes mellitus (Types 1 and 2) to support clinical and reimbursement decision-making. Curr. Med. Res. Opin. 20(Suppl. 1), S5\u2013S26 (2004).","journal-title":"Curr. Med. Res. Opin."},{"key":"e_1_3_7_25_2","unstructured":"NICE. Technology appraisal: empagliflozin in combination therapy for treating Type 2 diabetes (2015). https:\/\/www.nice.org.uk\/guidance\/ta336\/chapter\/3-The-companys-submission#cost\u2013effectiveness"},{"key":"e_1_3_7_26_2","unstructured":"IQVIA. CORE Diabetes Model: publications (2023). https:\/\/www.core-diabetes.com\/Index.aspx?Page=Publications"},{"key":"e_1_3_7_27_2","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the Economic Evaluation of Health Technologies (2017). https:\/\/www.cadth.ca\/dv\/guidelines-economic-evaluation-health-technologies-canada-4th-edition"},{"key":"e_1_3_7_28_2","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.2337\/dc10-0398","article-title":"Glycemic control and cardiovascular disease in 7,454 patients with Type 1 diabetes: an observational study from the Swedish National Diabetes Register (NDR)","volume":"33","author":"Eeg-Olofsson K","year":"2010","unstructured":"Eeg-Olofsson K, Cederholm J, Nilsson PM Glycemic control and cardiovascular disease in 7,454 patients with Type 1 diabetes: an observational study from the Swedish National Diabetes Register (NDR). Diabetes Care 33, 1640\u20131646 (2010).","journal-title":"Diabetes Care"},{"key":"e_1_3_7_29_2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s13300-020-00980-1","article-title":"Smart insulin pens are associated with improved clinical outcomes at lower cost versus standard-of-care treatment of Type 1 diabetes in Sweden: a cost\u2013effectiveness analysis","volume":"12","author":"Jendle J","year":"2021","unstructured":"Jendle J, Ericsson \u00c5, Gundgaard J Smart insulin pens are associated with improved clinical outcomes at lower cost versus standard-of-care treatment of Type 1 diabetes in Sweden: a cost\u2013effectiveness analysis. Diabetes Ther. 12, 373\u2013388 (2021).","journal-title":"Diabetes Ther."},{"key":"e_1_3_7_30_2","unstructured":"Health Canada. Canadian Tobacco Alcohol and Drugs Survey (CTADS): summary of results (2017). https:\/\/www.canada.ca\/en\/health-canada\/services\/canadian-alcohol-drugs-survey\/2017-summary.html"},{"key":"e_1_3_7_31_2","unstructured":"World Health Organization (WHO). Global status report on alcohol and healthGlobal status report on alcohol and health (2018). https:\/\/www.who.int\/publications\/i\/item\/9789241565639"},{"key":"e_1_3_7_32_2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/dia.2018.0310","article-title":"The relationship of hemoglobin A1C to time-in-range in patients with diabetes","volume":"21","author":"Vigersky RA","year":"2019","unstructured":"Vigersky RA, McMahon C. The relationship of hemoglobin A1C to time-in-range in patients with diabetes. Diabetes Technol. Ther. 21, 81\u201385 (2019).","journal-title":"Diabetes Technol. Ther."},{"key":"e_1_3_7_33_2","doi-asserted-by":"crossref","first-page":"309S","DOI":"10.1093\/ajh\/6.11.309S","article-title":"Coronary artery disease prediction","volume":"6","author":"Wilson PW","year":"1993","unstructured":"Wilson PW, Evans JC. Coronary artery disease prediction. Am. J. Hypertens. 6, 309S\u2013313S (1993).","journal-title":"Am. J. Hypertens."},{"key":"e_1_3_7_34_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2337\/dc13-2112","article-title":"The diabetes control and complications trial\/epidemiology of diabetes interventions and complications study at 30 years: overview","volume":"37","author":"Nathan DM","year":"2014","unstructured":"Nathan DM. The diabetes control and complications trial\/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care 37, 9\u201316 (2014).","journal-title":"Diabetes Care"},{"key":"e_1_3_7_35_2","unstructured":"Government of Ontario. Ontario Drug Benefit Formualry (2022). https:\/\/www.formulary.health.gov.on.ca\/formulary\/"},{"key":"e_1_3_7_36_2","unstructured":"Ontario Ministry of Health and Long Term Care (MHLTC). Schedule of benefits for Physician Services Under the Health Insurance Act (2022). http:\/\/www.health.gov.on.ca\/en\/pro\/programs\/ohip\/sob\/sob_mn.html"},{"key":"e_1_3_7_37_2","unstructured":"Canadian Institute for Health Information (CIHI). Patient Cost Estimator (2019). https:\/\/www.cihi.ca\/en\/patient-cost-estimator"},{"key":"e_1_3_7_38_2","unstructured":"CADTH. New drugs for Type 2 diabetes: second-line therapy \u2013 science report (2017). https:\/\/cadth.ca\/sites\/default\/files\/pdf\/TR0012_T2D_Science_Report.pdf"},{"key":"e_1_3_7_39_2","unstructured":"Statistics Canada. Table 18-10-0004-01 Consumer Price Index monthly not seasonally adjusted (2021). https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1810000401"},{"key":"e_1_3_7_40_2","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1177\/0272989X16658660","article-title":"The impact of diabetes-related complications on preference-based measures of health-related quality of life in adults with Type 1 diabetes","volume":"36","author":"Peasgood T","year":"2016","unstructured":"Peasgood T, Brennan A, Mansell P The impact of diabetes-related complications on preference-based measures of health-related quality of life in adults with Type 1 diabetes. Med. Decis. Making 36, 1020\u20131033 (2016).","journal-title":"Med. Decis. Making"},{"key":"e_1_3_7_41_2","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3111\/13696998.2011.579213","article-title":"Cost-utility of exenatide once weekly compared with insulin glargine in patients with Type 2 diabetes in the UK","volume":"14","author":"Beaudet A","year":"2011","unstructured":"Beaudet A, Palmer JL, Timlin L Cost-utility of exenatide once weekly compared with insulin glargine in patients with Type 2 diabetes in the UK. J. Med. Econ. 14, 357\u2013366 (2011).","journal-title":"J. Med. Econ."},{"key":"e_1_3_7_42_2","unstructured":"Statistics Canada. Table 13-10-0392-01 Deaths and age-specific mortality rates by selected grouped causes (2019 July 2021). https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1310039201"},{"key":"e_1_3_7_43_2","unstructured":"Statistics Canada. Table 13-10-0837-01 Life expectancy and other elements of the complete life table single-year estimates Quebec (2019). https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/cv.action?pid=1310083701"},{"key":"e_1_3_7_44_2","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.3390\/curroncol29030127","article-title":"Health technology assessment process for oncology drugs: impact of CADTH changes on public payer reimbursement recommendations","volume":"29","author":"Binder L","year":"2022","unstructured":"Binder L, Ghadban M, Sit C, Barnard K. Health technology assessment process for oncology drugs: impact of CADTH changes on public payer reimbursement recommendations. Curr. Oncol. 29, 1514\u20131526 (2022).","journal-title":"Curr. Oncol."},{"key":"e_1_3_7_45_2","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jval.2017.03.011","article-title":"Towards integrated health technology assessment for improving decision making in selected countries","volume":"20","author":"Oortwijn W","year":"2017","unstructured":"Oortwijn W, Determann D, Schiffers K, Tan SS, van der Tuin J. Towards integrated health technology assessment for improving decision making in selected countries. Value Health 20, 1121\u20131130 (2017).","journal-title":"Value Health"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2023-0124","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T09:55:14Z","timestamp":1709286914000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2023-0124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.57264\/cer-2023-0124"],"URL":"https:\/\/doi.org\/10.57264\/cer-2023-0124","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]},"article-number":"e230124"}}